Lung Cancer Remains the World’s Deadliest Cancer, and the Numbers Keep Climbing
Lung cancer sits at the center of the global cancer burden in 2024, with an estimated 2.6 million diagnoses and about 1.9 million deaths. Those figures make it the most common cancer type worldwide and the leading cause of cancer death, accounting for more than 1 in 8 cancer diagnoses and almost 1 in 5 cancer deaths in a single year. The scale alone explains why lung cancer research cannot be confined to treatment alone; prevention, screening, risk prediction, and tumor biology all have to move at once.
Public health exposure remains the dominant force behind the disease. Tobacco smoking is still the most common cause of lung cancer globally, but the burden does not stop there. Second-hand tobacco smoke, outdoor and indoor air pollution, diesel engine exhaust, welding fumes, and asbestos all contribute to risk, turning lung cancer into both a clinical and an environmental disease. The pathology is cumulative: repeated injury to the airway epithelium and lung parenchyma creates the conditions for malignant transformation over years, often long before symptoms emerge.
Screening Strategy Is Shifting Toward Risk, Not Just Age
A recent IARC Working Group convened under the IARC Handbooks of Cancer Prevention evaluated the benefits and harms of lung cancer screening. The conclusions were summarized in a Special Report published in The New England Journal of Medicine, with the detailed assessments due to appear in IARC Handbooks Volume 21. The broad clinical direction is already visible: screening must find the people most likely to benefit while limiting unnecessary imaging, false positives, and downstream procedures.
Risk prediction models are central to that shift. IARC research suggests that using models to determine eligibility for lung cancer screening could produce a better balance of benefits and harms than criteria currently used in some countries. The models also appear to narrow differences across racial and ethnic groups, which matters because eligibility rules based only on coarse demographic cutoffs can miss high-risk people and over-enroll lower-risk ones. In practical terms, a more precise screening strategy means fewer missed cancers and fewer invasive follow-up tests in people unlikely to benefit.
A single age cutoff is an imperfect proxy for carcinogenic exposure.
That limitation has real clinical consequences in a disease driven by long-term tobacco exposure and heterogeneous environmental risk. Screening works best when it is tied to actual probability of disease, not just years lived. Risk-based selection attempts to align CT screening with biological reality: the people most likely to harbor early malignant change are the ones who have accumulated the greatest exposure burden or carry other measurable risk markers.
Tobacco Control Could Prevent Millions of Future Cancers
IARC researchers also modeled the effect of full implementation of WHO Framework Convention on Tobacco Control measures in East and South-East Asia. The study estimated that approximately 3.5 million cancer cases could be prevented over the next 25 years if those policies were fully carried out. The implication reaches far beyond one cancer type, but lung cancer sits at the center of the projection because tobacco remains its major driver.
The logic is straightforward and biologically consistent. Reducing tobacco initiation, increasing cessation, and restricting exposure to tobacco smoke cuts the carcinogenic insult before it can seed the mutational cascade that leads to lung cancer. Unlike screening, which aims to find cancer earlier, tobacco control aims to prevent the malignant clone from ever appearing. In population terms, the difference is enormous: prevention can outperform treatment before the first scan is ever ordered.
Molecular Subtypes of Lung Neuroendocrine Tumours Are More Complex Than Grade Alone
IARC work on tumour classification has added another layer of clinical relevance by identifying four molecular groups of lung neuroendocrine tumours. In current practice, these tumors are simply defined as grade 1 or grade 2, yet the molecular analysis showed that each group contains both grades. One group was enriched for the highly aggressive supra-carcinoids, which means that histologic grade alone does not fully capture biological behavior.
This matters because classification is not just taxonomy. Better subgrouping can change how clinicians think about prognosis, surveillance, and management. A tumor that looks similar under the microscope may behave differently if its molecular drivers place it in a more aggressive category. For a cancer type whose incidence is increasing rapidly worldwide, a more accurate framework can help avoid both undertreatment and overtreatment.
Molecular profiling is exposing the gap between visual grading and biologic aggressiveness.
That gap is especially important in neuroendocrine disease, where proliferative rate, differentiation, and signaling pathways can influence how quickly the cancer spreads and how it responds to therapy. If a subgroup is enriched for supra-carcinoids, then grade alone can blur clinically meaningful differences. Precision classification offers a route to more rational decisions in pathology reports, clinical follow-up, and future trial design.
What the New Evidence Means for Bedside Practice
Lung cancer control now depends on several linked strategies rather than a single breakthrough. Tobacco control remains the most powerful population intervention. Screening can save lives when it is targeted to people at sufficiently high risk. Molecular classification can refine diagnosis and better align treatment with tumor biology. Each line of work addresses a different point in the disease course, from exposure to detection to prognosis.
For clinicians, the immediate consequence is a wider responsibility in risk assessment. Smoking history still matters, but so do exposure to indoor and outdoor air pollution, occupational hazards, and the possibility that traditional eligibility rules may miss patients with substantial risk. For pathologists and oncologists, the classification advances in neuroendocrine tumors point toward a future in which morphology and molecular data are read together rather than separately.
The article leaves open several questions that will determine how quickly these findings translate into routine practice: how countries will operationalize risk-based screening, how much local tobacco policies will actually reduce incidence, and how molecular tumor grouping will be incorporated into standard pathology workflows. The evidence points in the same direction, but implementation will decide whether the burden of lung cancer begins to fall.